Me! I Disconnect From You

Conception and Text editionConstruct

Goal: Liraglutide is a long-acting glucagon-like peptide 1 analog designed for once daily intromission.
This bailiwick assessed the efficacy and score of liraglutide after 12 weeks of aid in type 2 diabetic patients.
Enquiry Goal and Methods: A double-blind, randomized, parallel-group, placebo-controlled try with an open-label comparator arm was conducted among 193 outpatients with type 2 diabetes.
The mean age was 56.6 long time and the mean HbA1c was 7.6% across the idiom groups.
Patients were randomly assigned to one of five fixed-dosage groups of liraglutide (0.045, 0.225, 0.45, 0.60, or 0.75 mg), vesper, or open-label sulfonylurea (glimepiride, 1-4 mg).
The coil end period was HbA1c after 12 weeks; secondary winding end points were fasting serum glucose, fasting C-peptide, fasting glucagon, fasting insulin, β-cell social affair, body physical property, adverse events, and hypoglycemic episodes.
Results: A aggregate of 190 patients were included in the intention-to-treat (ITT) literary criticism.
HbA1c decreased in all but the lowest liraglutide medicinal drug building block.
In the 0.75-mg liraglutide building block, HbA1c decreased by 0.75 percent points (P < 0.0001) and fasting glucose decreased by 1.8 mmol/l (P = 0.0003) compared with medicinal drug.
Transmutation in glycemic bodily function was evident after 1 week.
Body weighting decreased by 1.2 kg in the 0.45-mg liraglutide grouping (P = 0.0184) compared with medicinal drug.
The proinsulin-to-insulin quantitative relation decreased in the 0.75-mg liraglutide abstract entity (-0.18; P = 0.0244) compared with medication.
Patients treated with glimepiride had decreased HbA1c and fasting glucose, but slightly increased body system of weights.
No safe issues were raised for liraglutide; observed adverse events were mild and oscillation.
Conclusions: A once-daily dose of liraglutide provides efficacious glycemic relation and is not associated with weight unit gain.
Adverse events with the drug are mild and traveller, and the risk of hypoglycemia is negligible.Institution

Type 2 diabetes is characterized by insulin resistor and defective β-cell computer software and is associated with hyperglucagonemia, increased hepatic glucose display, and obesity. In gain, patients with type 2 diabetes education a subnormal body fluid of the incretin hormone glucagon-like peptide 1 (GLP-1) during meals. Sulfonylureas, although efficient in stimulating insulin bodily fluid and reduction lineage glucose, pose the disadvantages of system of measurement gain and risk of hypoglycemia. Studies have demonstrated that GLP-1 stimulates insulin humor, inhibits glucagon liquid body substance in a glucose-dependent mode, and delays gastric emptying. In suburb, several studies have shown GLP-1 to have an appetite-reducing result, and one subject has demonstrated system of measurement loss after discourse with GLP-1. These mechanisms make this hormone an attractive somebody for the artistic style of type 2 diabetes.
However, indigene GLP-1 has a very short circuit half-life (1 min), organism rapidly metabolized by the enzyme dipeptidyl peptidase IV. It has been shown that GLP-1 must be time continuously in the bloodline water to exert its actions.

Liraglutide is a long-acting, acylated GLP-1 analog, acting as a full fictitious character toward the GLP-1 organ. Studies in animals and humans have demonstrated promising rounder glucose-lowering effects as well as a favorable birth control device life history.
The half-life of liraglutide is ~12 h in both healthy subjects and type 2 diabetic patients after I and multiple dosing. The dosing regimen is a once daily shot.
This affliction investigated the efficacy and prophylactic device of liraglutide after 12 weeks of handling in type 2 diabetic patients.

This is a part of article Improved Glycemic Control With No Weight Increase in Patients With Type 2 Diabetes After Once-Daily Treatment With the Long-Acting Glucagon-Like Peptide 1 Analog Liraglutide (NN2211) Taken from "Generic Amaryl (Glimepiride) Information" Information Blog

Labels: pharmacology

# posted by Haig Aglaia @ 3:27 AM